期刊文献+

乳腺癌组织多药耐药相关蛋白表达及其与化疗敏感性关系的研究 被引量:9

Correlation between sensitiviy of neoadjuvant chemotherapy and multidrug-resistance in breast carcinoma
下载PDF
导出
摘要 目的:探讨3种耐药相关蛋白P-gp、GST-π和TopoⅡ在乳腺癌组织中的表达及其与乳腺癌新辅助化疗敏感性的相关性。方法:乳腺癌患者80例,随机分为应用新辅助化疗(CEF)组(A组)和未化疗组(B组),A组应用新辅助化疗2周期,化疗前后分别行B超检查测量肿瘤大小。采用S-P免疫组织化学法检测80例乳腺癌组织中P-gp、GST-π和TopoⅡ的表达情况。结果:P-gp的表达在A组较B组有显著升高(P<0.05);GST-π和TopoⅡ的表达在A组及B组的表达差异无统计学意义(P>0.05)。A组P-gp的表达情况与乳腺癌肿瘤的缩小呈直线相关(P<0.05);GST-π、TopoⅡ的表达情况与乳腺癌瘤体的缩小无明显相关(P>0.05)。P-gp的表达与腋窝淋巴结阳性有显著相关;GST-π的表达与肿瘤的分级有显著相关,与雌激素受体呈负相关;TopoⅡ的表达与肿瘤的分级呈正相关。结论:P-gp的表达可能与乳腺癌的获得性耐药有关,GST-π和TopoⅡ的表达可能与乳腺癌的天然耐药有关。 Objective:To study the expressions of P-gp、GST-π、TopoⅡin breast carcinoma and the relationship between the drug resistance-associated proteins and the sensitivity of neoadjuvant chemotherapy of breast carcinoma.Methods:Eighty specimens of breast carcinoma were collected and the patients were classified randomly into group A and group B.Neoadjuvant chemotherapy(CEF)was used in group A,and we respectively measured maximum diameters of the tumors by B-ultrasound examination before and after the chemotherapy.we measured the expression of P-gp、GST-π、TopoⅡin 80 specimens by immunohistochemical technique(S-P).Results:The expression of P-gp increased significantly in group A compared with group B(P〈0.05).In group A,a significant linear correlation was observed between P-gp and the percentage of decrease of tumor(P〈0.05).The expression of P-gp was significantly associated with positive axillary node.The expression of GST-π was significantly associated with the pathologic class of tumor,and a negative correlation was found between GST-πand ER.A positive correlation was found between TopoⅡand the pathologic class of tumor.Conclusions:P-gp perhaps has a close relationship with acquired resistance of breast carcinoma,GST-πand TopoⅡ perhaps have a close relationship with natural resistance of breast carcinoma.
出处 《中国现代普通外科进展》 CAS 2008年第5期412-415,共4页 Chinese Journal of Current Advances in General Surgery
关键词 多药耐药相关蛋白类 免疫组织化学 乳腺肿瘤 Multidrug resistance-associated proteins·Immunohistochemistry· Breast carcinoma
  • 相关文献

参考文献8

  • 1Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J]. Clin Oncol, 1998,16(8):2672-2685.
  • 2Dash N, Chafin SH, Johnson RR, et al. Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer[J]. A JR Am J Roentgenol, 1999,173(4): 911-917.
  • 3Garces CA, Cance WG. Neoadjuvant chemotherapy of breast cancer [J]. Am Surg, 2004,70(7):565-569.
  • 4Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy[J]. Eur Radiol, 2004,14(8):1371-1379.
  • 5Hung WK, Lau Y, Chan CM, et al. Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study [J]. Hong Kong Med J, 2000,6(3):265-268.
  • 6Motohashi N, Kurihara T, Kawase M, et al. Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimidoand chloroethyl -phenothiazines[J].Anticancer Res, 1997,17 (5A):3537- 3543.
  • 7Cheung YC, Chen SC, Su MY, et al. Monitoring the size and re-sponse of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI [J]. Breast Cancer Res Treat, 2003,78(1):51-58.
  • 8Akashi Tanaka S, Fukutomi T, Sato N, et al. The use of contrastenhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery[J]. Ann Surg, 2004,239(2):238-243.

同被引文献97

引证文献9

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部